TTR and prealbumin measurement: In another study, Intellia Therapeutics again developed NTLA‐2001 gene therapy, which is a CRISPR/Cas9 system to knock out the transthyretin (TTR) gene in patients with the progressive, fatal disease hereditary transthyretin amyloidosis, which is caused by mutation of the TTR gene.